Related Experiment Video

Updated: Jun 23, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Targeted delivery of drugs for liver fibrosis

Feng Li1, Ji-yao Wang

  • 1Zhongshan Hospital Affiliated to Fudan University, Department of Gastroenterology, 180 Fenglin Road, Shanghai, China. lifeng197881@yahoo.com.cn

Expert Opinion on Drug Delivery
|May 6, 2009
PubMed

Insights

Targeted delivery systems show promise for treating liver fibrosis by concentrating antifibrotic drugs at hepatic stellate cells (HSC). This approach overcomes limitations of traditional therapies, offering a new therapeutic pathway for liver disease.

Area of Science:

  • Hepatology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Liver fibrosis and cirrhosis are significant global health burdens with limited pharmaceutical treatments.
  • Current antifibrotic drugs often fail in vivo due to poor drug concentration at target cells and off-target effects.
  • Hepatic stellate cells (HSC) are key drivers of liver fibrogenesis, making them primary targets for antifibrotic therapies.

Purpose of the Study:

  • To review targeted delivery systems designed to specifically target hepatic stellate cells (HSC) for liver fibrosis treatment.
  • To evaluate the potential of these systems in enhancing drug efficacy and reducing side effects in vivo.

Main Methods:

  • Review of literature on targeted delivery systems for antifibrotic therapy.
  • Analysis of systems designed to target receptors expressed on HSC.
  • Evaluation of in vivo studies demonstrating the efficacy of drug-loaded targeted systems in animal models of liver fibrosis.

Main Results:

  • Several targeted delivery systems capable of targeting HSC have been developed.
  • These systems have demonstrated significant potential for concentrating therapeutic agents at HSC in vivo.
  • Drug-loaded targeted systems have shown potent antifibrotic effects in animal models.

Conclusions:

  • Targeted delivery systems offer a promising new strategy for the pharmaceutical intervention of liver fibrosis.
  • These systems can overcome the limitations of conventional drug delivery, improving therapeutic outcomes.
  • Further research into targeted carriers could revolutionize liver fibrosis treatment.

More Related Videos

Cell Type-specific Gene Expression Profiling in the Mouse Liver10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...